Senores Pharmaceuticals has issued a corporate guarantee of Rs 62 crore to ICICI Bank for its subsidiary, Apnar Pharma. This secures credit facilities for Apnar Pharma and adds a contingent liability to Senores Pharma's books.
Senores Pharmaceuticals Ltd. Guarantees INR 62 Crore for Subsidiary Credit Facilities
Senores Pharmaceuticals Ltd. has provided a corporate guarantee of INR 62 crore to ICICI Bank Limited. This guarantee is intended to secure credit facilities sanctioned to its wholly-owned subsidiary, Apnar Pharma Private Limited. ## What Just Happened Senores Pharmaceuticals has issued a corporate guarantee amounting to INR 62 crore to ICICI Bank. This financial backing is for credit facilities extended to its subsidiary, Apnar Pharma Private Limited. ## Why This Matters This move signifies Senores Pharmaceuticals' commitment to supporting its subsidiary's financial needs. While it doesn't immediately affect the parent company's profits or cash flow, it creates a contingent liability on Senores Pharmaceuticals' balance sheet, indicating a potential future obligation. ## The Backstory Senores Pharmaceuticals Ltd. is a pharmaceutical company. Apnar Pharma Private Limited is its subsidiary. The corporate guarantee is a standard financial instrument used to support the borrowing capabilities of a subsidiary. ## What Changes Now For Senores Pharmaceuticals, the primary change is the recording of this INR 62 crore guarantee as a contingent liability in its financial statements. This will be disclosed as per SEBI regulations. The guarantee remains valid until Apnar Pharma's credit facilities are fully settled. ## Risks to Watch The main risk is that if Apnar Pharma defaults on its credit facilities, Senores Pharmaceuticals will be obligated to repay the INR 62 crore to ICICI Bank. The company states the transaction is at "arm's length" and notes promoter/promoter group interest via directorships in the subsidiary. ## Peer Comparison Providing corporate guarantees for subsidiaries is a common practice in the pharmaceutical industry to facilitate easier access to credit for operational expansion or working capital needs. ## Context Metrics As of August 24, 2026, the guarantee is INR 62 crore and is valid until the closure of the credit facilities. ## What to Track Next Investors should monitor the financial health and debt servicing capabilities of Apnar Pharma Private Limited. Any developments regarding the status of these credit facilities should also be tracked.
